A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenet… (NCT05677438) | Clinical Trial Compass
CompletedPhase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia
South Korea121 participantsStarted 2022-12-20
Plain-language summary
This is a multi-centers, randomized, double-blind, parallel-group, Phase 2 Trial to evaluate the efficacy and safety of CKD-498 in female patients with Androgenetic Alopecia
Who can participate
Age range19 Years – 54 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Key Inclusion Criteria:
* Female of age 19-54 years
* Clinical Diagnosis of Androgenetic Alopecia
* Written informed consent
Key Exclusion Criteria:
* Other types of Alopecia or other diseases that can cause hair loss
* Clinically significant scalp disease such as seborrheic dermatitis or psoriasis
* Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator
* Women who are pregnant or breastfeeding
* Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the last dose of study drug